BioAlliance Pharma in-licenses new pipeline project


Paris – BioAlliancePharma has filled its early-stage pipeline with Odansentron. The 5-HT3 compound is already marketed as a tablet, and now BioAlliance is planning to develop it as a mouth spray. “This fits well into our strategy to expand our presence in supportive care for oncology patients, and to focus on patient convenience,” company CEO Dominique Constantini told EuroBiotechNews. BioAlliance paid US$3m for the European rights for the Odansentron spray in advance to US-based NovaDel Pharma Inc. The out-licensor is also eligible for milestones potentially amounting to US$24m. Bio­Alliance’s responsibility will be to bring the product to market in Europe. In the US, NovaDel’s partner Par Pharmaceutical is responsible for the clinical development and the US registration. BioAlliance will use these documents for the European application. Par and BioAlliance are already cooperating on Loramyc, which is a novel miconazole lozenge-formulation against oral candidiasis.
The Euronext-listed BioAlliance focuses on specialty pharma products sold in the hospital. The company launched Loramyc last year in cooperation with Dutch Spe-pharm in Europe. Bio­Alliance is running two Phase III trials with Acyclovir, a tablet against labial herpes, and with a new formulation of Doxorubicin. To overcome resistance issues, the approved chemotherapeutic was formulated with nanoparticles and masked by sugar residues. BioAlliance pharma has EUR56m in the bank, and is currently burning almost EUR20m per year. In 2012, the company aims to have four products on the market.



Marcy l’Etoile – French in vitro diagnostics group Biomérieux S.A. informed the markets that it has acquired Argene, a French company specialising in molecular diagnostics for immuno­compromised patients. Biomérieux said it was...



Paris – A team consisting of French scientists and biotech start-up Epixis SA has developed a novel hepatitis C vaccine based on retrovirus-derived virus-like particles (VLPs) pseudotyped with the heterologous viral envelope...



Neuilly/New York - Les Laboratoires Servier and Intercept Pharmaceuticals join forces for the development of diabetes drugs. France’s largest independent pharmaceutical company and the US biotech entered into a worldwide ex-U.S....



Paris/New Haven - Sanofi pays a $9m milestone payment to Rib-X Pharmaceuticals, Inc. The French pharmaceutical company recently signed worldwide research collaboration and option for license for novel classes of antibiotics...



French drug maker Sanofi SA announced mixed results of a late-stage trial of multiple sclerosis drug Lemtrada. The two-year study CARE-MS I is the first of two randomised, Phase 3 clinical trials comparing Sanofi's alemtuzumab to...



French Biotech BioAlliance Pharma S.A. has announced plans to raise up toEUR 16.6 million through the sale 3.4 million shares at EUR 4.90 in a rightsissue. The price is a 20% discount to BioAlliance's closing price of EUR6.10...



Paris – Pulmonary arterial hypertension (PAH), a severe disease of the arterial blood vessels in the lungs, leads to chronically elevated pulmonary artery pressure and remodelling of the small pulmonary arteries (SMPs) as a...

Displaying results 21 to 30 out of 268

< Previous 21-30 Next >

© 2007-2015 BIOCOM

Job Advert

Sales Manager

celares GmbH is a Berlin based drug delivery company focused on chemical modifications of biological drugs. We offer customized development services for international pharma and biopharma companies and have manufacturing capabilities for key starting materials used for the preparation of pharmaceutical drugs. For the intensification of our own sales activities we are looking for a sales manager. more...

Product of the week



All videos


All Events

Stock list

All quotes


  • 4SC1.28 EUR52.38%
  • THERAMETRICS0.08 CHF14.29%
  • WILEX2.96 EUR1.37%


  • MOLOGEN5.68 EUR-28.01%
  • MORPHOSYS54.71 EUR-22.45%
  • MEDIGENE11.65 EUR-13.70%


  • CYTOS1.40 CHF311.8%
  • MEDIGENE11.65 EUR174.1%
  • 4SC1.28 EUR64.1%


  • MORPHOSYS54.71 EUR-26.8%
  • WILEX2.96 EUR-13.7%
  • BASILEA106.70 CHF-12.7%


  • SANTHERA92.00 CHF2259.0%
  • WILEX2.96 EUR393.3%
  • FORMYCON23.15 EUR232.6%


  • CYTOS1.40 CHF-54.2%
  • MOLOGEN5.68 EUR-49.9%
  • PAION2.35 EUR-29.6%

No liability assumed, Date: 26.03.2015

Current issue

All issues